MedTrace Logo

Assessment of FOXP3 Gene Polymorphisms and Serum Interleukin 10 in Patients With ITP

NCT05410249 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2023-04-12

No results posted yet for this study

Summary

Immune thrombocytopenia (ITP) is an autoimmune condition characterized by increased platelet destruction and suppression of production resulting in isolated thrombocytopenia. The exact etiology of ITP is unknown; however, multiple disease mechanisms exist and are mostly related to immune dysregulation \[1\].

Many studies in recent years have indicated that regulatory T cells (Tregs) play a critical role in the maintenance of immunological tolerance, and they have been reported to be defective in ITP patients, either numerically or functionally. \[2-6\]. They inhibit the activation and proliferation of effector T cells by the secretion of cytokines such as interleukin-10 (IL-10) and tumor growth factor-β (TGF-β) and by cell-to-cell interaction \[7, 8\].

Conditions

Interventions

DIAGNOSTIC_TEST

Serum IL10 By ELISA

measurement Of IL10 by ELISA

DIAGNOSTIC_TEST

SNP -3279 A/C of FOXP3

Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.

DIAGNOSTIC_TEST

SNP-924 A/G Of FOXP3

Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Asmaa A Abdelbaset, lecturer · faculty of medicine, Sohag university

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2022-12-26
Completion
2023-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05410249 on ClinicalTrials.gov